AN2 Therapeutics, Inc. (ANTX)
3.55
-0.09
(-2.47%)
USD |
NASDAQ |
Oct 23, 16:00
3.555
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Net Income (Quarterly) : -8.185M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.185M |
| March 31, 2026 | -10.03M |
| December 31, 2025 | -8.71M |
| September 30, 2025 | -9.353M |
| June 30, 2025 | -6.462M |
| March 31, 2025 | -10.65M |
| December 31, 2024 | -7.522M |
| September 30, 2024 | -12.75M |
| June 30, 2024 | -14.44M |
| March 31, 2024 | -16.62M |
| Date | Value |
|---|---|
| December 31, 2023 | -16.90M |
| September 30, 2023 | -16.71M |
| June 30, 2023 | -15.80M |
| March 31, 2023 | -15.32M |
| December 31, 2022 | -11.84M |
| September 30, 2022 | -11.34M |
| June 30, 2022 | -10.12M |
| March 31, 2022 | -7.655M |
| December 31, 2021 | -7.545M |
| September 30, 2021 | -6.943M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -3.164M |
| CNBX Pharmaceuticals, Inc. | -0.1542M |
| Arvinas, Inc. | 169.40M |
| Fulcrum Therapeutics, Inc. | -26.18M |
| Definium Therapeutics, Inc. | -158.99M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 8.185M |
| EPS Diluted (Quarterly) | -0.1829 |
| Enterprise Value | 50.51M |
| Earnings Yield | -30.23% |
| Normalized Earnings Yield | -30.23 |